Abstract
Background: Few data are available on compliance and safety of adjuvant chemotherapy when indicated in elderly breast cancer patients; CMF (cyclophosphamide, methotrexate, fluorouracil) can be reasonably considered the most widely accepted standard of treatment. Methods: We retrospectively reviewed compliance and safety of adjuvant CMF in patients older than 60. The treatment was indicated if patients had no severe comorbidity, a high-risk of recurrence, and were younger than 75. Toxicity was coded by NCI-CTC. Toxicity and compliance were compared between two age subgroups (
Original language | English |
---|---|
Article number | 30 |
Journal | BMC Cancer |
Volume | 5 |
DOIs | |
Publication status | Published - Mar 24 2005 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
- Genetics